Placental Transcriptomics and Risk for Schizophrenia - Our main objective is to find the factors mediating the relationship between genetic risk
factors, complications in early life (ELCs, i.e. pre-, and perinatal) and altered neuro-
development (ND) in humans, so that, in high-risk individuals, disorders of ND such as
schizophrenia (SZ), can be prevented or rescued in early stages. Epidemiological findings
show that ELCs increase the risk for ND disorders including SZ; preclinical models show
that ELCs alter ND, an effect partially mediated by gene expression in placenta, with males
more vulnerable than females. However, the mechanism linking ELCs with SZ are still
elusive. Our recent human work found that genetic factors converge with placenta biology
in affecting risk for SZ. Here, we focus on detecting the molecular mediators involved: that
is, the molecules that, by regulating placenta's physiology, regulate ND, drive susceptibility
to SZ, and may mediate the interaction between genetic factors and ELCs on the risk for
the disorder. We propose a multi-step strategy, which leverages our strengths in analyzing
transcriptomic and genetic data, using well-established and innovative methodologies to
explore a novel area of research: the relationship between genomic risk factors, placenta
and SZ. We will first investigate the transcriptomic correlates of genetic risk factors for SZ
in the placenta, and we will analyze whether gene isoforms associated with risk for SZ are
co-expressed in placenta, as part of specific biological processes. Using genotype-based
prediction of gene expression in large cohorts, we will identify the specific placental
isoforms associated with SZ case-control status. We will then generate placental genomic
predictors of SZ risk, and we will test their relationship with ND outcomes. To investigate
sex-specific placental processes relevant for SZ, we will stratify each analysis by sex. We
expect our data to converge in identifying placental molecules and pathways that are
relevant for SZ. The detection of such molecules may be translated into the development
of novel prenatal prevention of SZ, aimed at preserving / optimizing the important placental
support to ND, and the development of novel postnatal prevention, based on the
identification of high-risk individuals – through placental and genetic biomarkers.